Prevalence of non-alcoholic fatty liver disease and its predictors in North of Iran

Iranian Journal of Public Health

Volumn 43, Issue 9, 2014, Pages 1275-1283

  Amirkalali, Bahareh ^a   Poustchi, Hossein ^b   Keyvani, Hossein ^c   Khansari, Mahmood Reza ^a   Ajdarkosh, Hossein ^a   Maadi, Mansooreh ^a   Sohrabi, Masoud Reza ^a   Zamani, Farhad ^a  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Metabolic syndrome; Non Alcoholic fatty liver disease (NAFLD); Risk factors

Indexed keywords

EID: 84911465799     PISSN: 22516085     EISSN: 22516093     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Alba L, Lindor K (2003). Non-alcoholic fatty liver disease. Aliment Pharmacol Ther,17 (8): 977-86.
2. Angulo P (2007). GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther, 25 (8): 883-9.
3. Clark JM, Brancati FL, Diehl AM (2002). Nonalcoholic fatty liver disease. Gastroenterology, 122 (6): 1649-57.
4. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. (2005). Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology, 41 (6): 1313-21.
5. Lattuada G, Ragogna F, Perseghin G (2011). Why Does NAFLD Predict Type 2 Diabetes? Curr Diab Rep, 11 (3): 167-72.
6. FAN JGAO, Zhu J, LI XJ, Chen L, LU YSAN, Li L, et al. (2005). Fatty liver and the metabolic syndrome among Shanghai adults. J Gastroenterol Hepatol, 20 (12): 1825-32.
7. Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, et al. (2005). The Metabolic Syndrome as a Predictor of Nonalcoholic Fatty Liver Disease. Ann Intern Med, 143 (10): 722-28.
8. Jeong SK, Kim YK, Park JW, Shin YJ, Kim DS (2008). Impact of visceral fat on the metabolic syndrome and nonalcoholic fatty liver disease. J Korean Med Sci, 23 (5): 789-95.
9. Neuschwander-Tetri BA, Caldwell SH (2003). Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology, 37 (5): 1202-19.
10. Bedogni G, Bellentani S (2004). Fatty liver: how frequent is it and why. Ann Hepatol, 3 (2): 63-5.
11. Lee JY, Kim KM, Lee SG, Yu E, Lim YS, Lee HC, et al. (2007). Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center. J Hepatol, 47 (2): 239-44.
12. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S (2005). Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology, 42 (1): 44-52.
13. Zelber-Sagi S, Nitzan-Kaluski D, Halpern Z, Oren R (2006). Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures. Liver Int, 26 (7): 856-63.
14. Chen CH, Huang MH, Yang JC, Nien CK, Yang CC, Yeh YH, et al. (2006). Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of Taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults. J Clin Gastroenterol, 40 (8): 745-52.
15. Fan JG, Saibara T, Chitturi S, Kim BI, Sung JJY, Chutaputti A (2007). What are the risk factors and settings for non-alcoholic fatty liver disease in Asia–Pacific? J Gastroenterol Hepatol, 22 (6): 794-800.
16. Esteghamati A, Meysamie A, Khalilzadeh O, Rashidi A, Haghazali M, Asgari F, et al (2009). Third national surveillance of risk factors of non-communicable diseases (SuRFNCD- 2007) in Iran: methods and results on prevalence of diabetes, hypertension, obesity, central obesity, and dyslipidemia. BMC Public Health, 29 (9): 167.
17. Rogha M, Najafi N, Azari A, Kaji M, Pourmoghaddas Z, Rajabi F, et al. (2011). Nonalcoholic Steatohepatitis in a Sample of Iranian Adult Population: Age is a Risk Factor. Int J Prev Med, 2 (1): 24–7.
18. Jamali R, Khonsari M, Merat S, Khoshnia M, Jafari E, Bahram Kalhori A, et al (2008). Persistent alanine aminotransferase elevation among the general Iranian population: Prevalence and causes. World J Gastroenterol, 14 (18): 2867-71.
19. Sohrabpour A, Rezvan H, Amini-Kafiabad S, Dayhim MR, Merat Shahin, Pourshams A (2010). Prevalence of nonalcoholic steatohepatitis in Iran: A population based study. Mid East J Dig Dis, 2 (1): 14-9.
20. Hosseinpanah F, Rambod M, Sadeghi L (2007). Predictors of Non-Alcoholic Fatty Liver Disease in Type 2 Diabetese. Int J Endocrinol Metab, 2: 61-9.
21. Zamani F, Sohrabi M, Poustchi H, Keyvani H, Saeedian FS, Ajdarkosh H. (2013). Prevalence and Risk Factors of Hepatitis C Virus Infection in Amol City, North of Iran: A Population- Based Study (2008-2011). Hepat Mon, 13 (12): e13313.
22. McDowell MA (2005). Statistics NCfH, Control CfD, Prevention. Anthropometric reference data for children and adults: US population, 1999-2002: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics.
23. Sanyal AJ (2002). AGA technical review on nonalcoholic fatty liver disease. Gastroenterology, 123 (5): 1705-25.
24. Grundy SM, Hansen B, Smith Jr SC, Cleeman JI, Kahn RA (2004). Clinical management of metabolic syndrome. Circulation, 109 (4): 551-6.
25. Azizi F, Salehi P, Etemadi A, Zahedi-Asl S (2003). Prevalence of metabolic syndrome in an urban population: Tehran Lipid and Glucose Study. Diabetes Res Clin Pract, 61(1): 29-37.
26. Ludwig J, Viggiano TR, McGill DB, Oh BJ (1980). Nonalcoholic steatohepatitis. Mayo Clinic experiences with a hitherto unnamed disease: Mayo Clin Proc, 55 (7): 434-8.
27. Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ (2001). Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis, 21 (1): 17-26.
28. Bugianesi E, Manzini P, D'Antico S, Vanni E, Longo F, Leone N, et al. (2004). Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology, 39 (1): 179-87.
29. Harrison SA, Torgerson S, Hayashi PH (2003). The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol, 98 (9): 2042-7.
30. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. (2003). Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology, 37 (4): 917-23.
31. Fraser A, Longnecker MP, Lawlor DA (2007). Prevalence of elevated alanine aminotransferase among US adolescents and associated factors: NHANES 1999–2004. Gastroenterology, 133 (6): 1814-20.
32. Tominaga K, Kurata JH, Chen YK, Fujimoto E, Miyagawa S, Abe I, et al (1995). Prevalence of fatty liver in Japanese children and relationship to obesity. Dig Dis Sci, 40 (9): 2002-9.
33. Caballería L, Pera G, Auladell MA, Torán P, Muñoz L, Miranda D, et al. (2010). Prevalence and factors associated with the presence of nonalcoholic fatty liver disease in an adult population in Spain. Eur J Gastroenterol Hepatol, 22 (1): 24-32.
34. Park JW, Jeong G, Kim SJ, Kim MK, Park SM (2007). Predictors reflecting the pathological severity of non-alcoholic fatty liver disease: Comprehensive study of clinical and immunohistochemical findings in younger Asian patients. J Gastroenterol Hepatol, 22 (4): 491-7.
35. Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA, et al. (2003). Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology, 37 (6): 1286-92.
36. Prati D, Taioli E, Zanella A, Torre ED, Butelli S, Del Vecchio E, et al. (2002). Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med, 137 (1): 1-10.
37. Browning JD, Szczepaniak LS, Dobbins R, Horton JD, Cohen JC, Grundy SM, et al. (2004). Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology, 40 (6): 1387-95.
38. Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. (2006). Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology, 44 (4): 865-73.
39. Loria P, Lonardo A, Carulli N (2005). Should nonalcoholic fatty liver disease be renamed? Dig Dis, 23(1):72-82.
40. Caballería L, Auladell MA, Torán P, Miranda D, Aznar J, Pera G, et al. (2007). Prevalence and factors associated with the presence of non alcoholic fatty liver disease in an apparently healthy adult population in primary care units. BMC Gastroenterol, 7(1):41.
41. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, et al. (2002). The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology, 123 (3): 745-50.
42. Mottin CC, Moretto M, Padoin AV, Swarowsky AM, Toneto MG, Glock L, et al. (2004). The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese patients. Obes Surg, 14(5): 635-7.
43. Burcelin R, Serino M, Chabo C, Blasco-Baque V, Amar J (2011). Gut microbiota and diabetes: from pathogenesis to therapeutic perspective. Acta Diabetol, 48 (4): 257-73.